Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)

Richard Cathomas(Kantonsspital Graubünden), Silke Gillessen(Institute of Oncology Research), Simona Berardi Vilei(Swiss Group For Clinical Cancer Research), Gabriela Manetsch(Kantonsspital Graubünden), Christian Rothermundt, Stefanie Hayoz(Swiss Group For Clinical Cancer Research), Heike Kenner(Swiss Group For Clinical Cancer Research), Michael Mark(Kantonsspital Graubünden), Tony Elliott(The Christie Hospital), Simon J. Crabb(University of Southampton), Enrico Roggero, Markus G. Mohaupt, Jürg Bernhard(International Breast Cancer Study Group), Daniel Rauch(Washington University in St. Louis), Ralph Winterhalder(Luzerner Kantonsspital), Philippe von Burg(Kantonsspital Aarau)
The Prostate
July 25, 2016
10.1002/pros.23236
Cited by 20

Related Papers

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Editor's Choice – Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS)
|European Journal of Vascular and Endovascular Surgery|2018|829